ozoralizumab
mAbexperimental
Ozoralizumab is a trivalent anti-tumour necrosis factor alpha (TNFα) nanobody designed for the treatment of inflammatory diseases. — Wikipedia
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00916110)
Timeline
Indications
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
Trivalent albumin-binding nanobody that neutralizes the pro-inflammatory tumor necrosis factor alpha (TNF-alpha) as a causative agent for exacerbating rheumatoid arthritis. It binds to serum to increase its in vivo half-life.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOzoralizumab ↗
- ChEMBLCHEMBL1743054 ↗
Also known as
- atn-103
- atn-103
- ozoralizumab
- ozoralizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04077567 | Phase 3 | Oct 1, 2019 | Taisho Pharmaceutical |
| NCT01063803 | Phase 2 | Feb 1, 2010 | Ablynx |
| NCT01007175 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2009 | Ablynx |
| NCT00959036 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2009 | Ablynx |
| NCT00916110 | Phase 1 | Nov 1, 2008 | Ablynx |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ablynx | For profit | 4 | 4 | 2 | 2008 |
| Taisho Pharmaceutical | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1